middle.news
Alterity Therapeutics Secures A$7.8M to Accelerate ATH434 Trials After Positive Phase 2 Data
9:54am on Monday 3rd of February, 2025 AEDT
•
Biotechnology
Read Story
Alterity Therapeutics Secures A$7.8M to Accelerate ATH434 Trials After Positive Phase 2 Data
9:54am on Monday 3rd of February, 2025 AEDT
Key Points
Raised approximately A$2.13 million via U.S. at-the-market facility
Expected A$5.69 million in Australian R&D tax rebates in Q1 2025
Funding to accelerate clinical and business development of ATH434
Positive topline Phase 2 results in Multiple System Atrophy (MSA)
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE